A correspondence in The Lancet argues that the WILLOW trial's Cohort B results reveal a mismatch between the drug's biological mechanism and the composite endpoint chosen to measure it, complicating interpretation of the enpatoran dose-response data.
WILLOW Cohort B Analysis Questions Endpoint Design in Lupus Trials
A correspondence in The Lancet argues that the WILLOW trial's Cohort B results reveal a mismatch between the drug's biological mechanism and the composite endpoint chosen to measure it, complicating interpretation of the enpatoran dose-response data.
![[Correspondence] Mechanism–endpoint matching in lupus: WILLOW Cohort B](https://nbg1.your-objectstorage.com/ckln/image-assets/1b4477df787e1ccc7300f55e2674ffd661483cc0c83a6fa1357a32d6b795551a.jpg)
IAU and Sky & Telescope · CC BY 4.0 · rights
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.